ANKRD2

Across TCGA pan-cancer cohorts, ANKRD2 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of ANKRD2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where ANKRD2 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ANKRD2 is over-expressed in tumor, although a few such as CCRCC and HNSC show the opposite, repressed pattern.

CCRCC, HNSC, and PDAC are the cancer types where ANKRD2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ANKRD2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	III,IV	−1.330	<.001	12	view →
HNSC	All	All	−0.544	.027	6	view →
PDAC	Male	All	−0.817	.010	4	view →
LSCC	Male	All	−0.258	.023	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

ANKRD2–CCRCC

Open the CCRCC breakdown →